前立腺の健康市場：疾患タイプ、治療タイプ、薬物治療タイプ別-2025-2030年の世界予測

前立腺の健康市場は、2023年に521億3,000万米ドルと評価され、2024年には574億8,000万米ドルに達すると予測され、CAGR 10.74％で成長し、2030年には1,064億9,000万米ドルに達すると予測されています。

前立腺の健康市場には、前立腺の健康維持・改善を目的とした製品、サービス、治療が含まれます。これには、前立腺肥大症（BPH）、前立腺炎、前立腺がんなどの疾患を対象とした医薬品、外科手術、診断薬、栄養補助食品、医療機器などが含まれます。この市場の必要性は、人口の高齢化とライフスタイル要因に後押しされた前立腺関連疾患の有病率の増加によって裏付けられています。治療用途は予防ヘルスケアから高度な治療法まで多岐にわたり、最終用途は病院、専門クリニック、研究機関、患者のセルフケアなどです。主な市場促進要因としては、診断・治療法の技術進歩、意識の高まり、ヘルスケア支出の増加などが挙げられます。しかし、高額な治療費、投薬や処置による副作用、保険適用の問題などの制約が市場拡大の課題となっています。潜在的なビジネスチャンスは、個別化医療、遠隔患者管理のための遠隔医療、低侵襲手技の革新にあり、これらはますます牽引力を増しています。企業は、研究開発への投資、戦略的パートナーシップの形成、患者教育とエンゲージメントの強化のためのデジタル・プラットフォームの活用によって、これらを活用することができます。とはいえ、特に新薬承認に関する規制上の制約や、複数のプレーヤーが市場シェアを争う競合情勢などの課題には、慎重な対応が必要です。イノベーションは、より効果的で侵襲の少ない診断ツールの開発や、治療パラダイムを変革する可能性を秘めた生物製剤や遺伝子治療のブレークスルーを促進することに向けられると思われます。さらに、学術機関とバイオテクノロジー企業との協力関係を促進することで、研究に拍車がかかり、ベンチサイドからベッドサイドへの移行を促進することができます。市場の性質はダイナミックであり、技術の絶え間ない進歩や、患者やヘルスケア提供者の嗜好の変化によって左右されるため、戦略策定には俊敏性と先見性が求められます。したがって企業は、新たな動向や消費者ニーズへの柔軟性と対応力を確保し、適応力のあるビジネスモデルに焦点を当てるべきです。

市場力学：急速に進化する前立腺の健康市場の主要市場インサイトを公開

前立腺の健康市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 高齢化人口の増加と前立腺肥大症および前立腺がんの有病率の増加
  • 診断技術の進歩に対する政府のイニシアチブの高まり
  • ホルモン治療薬の技術革新とゲノミクスおよびプロテオミクスの発展
• 市場抑制要因
  • 前立腺肥大症治療薬に伴う副作用
• 市場機会
  • ルカパリブやオラパリブなどの新薬開発につながる研究の増加
  • 前立腺がんの新規治療法の開発
• 市場の課題
  • 前立腺の健康に関する認知度の低さ

ポーターの5つの力：前立腺の健康市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：前立腺の健康市場における外部からの影響の把握

外部マクロ環境要因は、前立腺の健康市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析前立腺の健康市場における競合情勢の把握

前立腺の健康市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス前立腺の健康市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、前立腺の健康市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨前立腺の健康市場における成功への道筋を描く

前立腺の健康市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢化人口の増加と前立腺肥大症および前立腺がんの罹患率の増加
    • 診断技術の向上に向けた政府の取り組みの拡大
    • ホルモン療法薬の革新とゲノミクスおよびプロテオミクスの開発
  • 抑制要因
    • BPH治療薬に伴う副作用
  • 機会
    • ルカパリブやオラパリブなどの新薬開発につながる研究の増加
    • 前立腺がんに対する新たな治療法の開発
  • 課題
    • 前立腺の健康に関する認知度が低い
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 前立腺の健康市場：疾患タイプ別

• 前立腺肥大症
• 前立腺がん
• 前立腺炎

第7章 前立腺の健康市場治療の種類別

• AR指向療法
• 細胞毒性剤
• ホルモンADT
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤

第8章 前立腺の健康市場薬物治療の種類別

• 5-α還元酵素阻害剤
  • デュタステリド
  • フィナステリド
• アルファ遮断薬
  • アルフゾシン
  • ドキサゾシン
  • シロドシン
  • タムスロシン

第9章 南北アメリカの前立腺の健康市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の前立腺の健康市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの前立腺の健康市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Elekta AB
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Ferring Pharmaceuticals Inc.
• GlaxoSmithKline PLC
• Ipsen Limited
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Ltd.

LIST OF FIGURES

• FIGURE 1. PROSTATE HEALTH MARKET RESEARCH PROCESS
• FIGURE 2. PROSTATE HEALTH MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. PROSTATE HEALTH MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. PROSTATE HEALTH MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PROSTATE HEALTH MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PROSTATE HEALTH MARKET DYNAMICS
• TABLE 7. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AR-DIRECTED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE ADT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PROSTATE HEALTH MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PROSTATE HEALTH MARKET SIZE, BY SILODOSIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 43. CANADA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. CANADA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CANADA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 47. CANADA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 70. CHINA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. CHINA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CHINA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 74. CHINA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 75. INDIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. INDIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 78. INDIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 79. INDIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 161. ITALY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 162. ITALY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 164. ITALY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 165. ITALY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 181. POLAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 182. POLAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 184. POLAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 185. POLAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 186. QATAR PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 187. QATAR PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 189. QATAR PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 190. QATAR PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
• TABLE 236. PROSTATE HEALTH MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 237. PROSTATE HEALTH MARKET, FPNV POSITIONING MATRIX, 2023

The Prostate Health Market was valued at USD 52.13 billion in 2023, expected to reach USD 57.48 billion in 2024, and is projected to grow at a CAGR of 10.74%, to USD 106.49 billion by 2030.

The prostate health market encompasses products, services, and treatments aimed at maintaining or improving the health of the prostate gland. This includes pharmaceuticals, surgical procedures, diagnostics, dietary supplements, and medical devices targeting conditions such as benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. The necessity of this market is underscored by the increasing prevalence of prostate-related disorders, fueled by aging populations and lifestyle factors. Applications span from preventive healthcare to advanced treatment methods, with end-use encompassing hospitals, specialty clinics, research institutes, and patient self-care. Key market growth drivers include technological advancements in diagnostics and treatment modalities, increasing awareness, and heightened healthcare expenditure. However, limitations such as high treatment costs, side effects of medications and procedures, and insurance coverage issues challenge market expansion. Potential opportunities lie in personalized medicine, telemedicine for remote patient management, and innovations in minimally invasive procedures, which are increasingly gaining traction. Businesses can capitalize on these by investing in R&D, forming strategic partnerships, and leveraging digital platforms for enhanced patient education and engagement. Nonetheless, challenges such as regulatory constraints, particularly on new drug approvals, and the competitive landscape with several players vying for market share, require careful navigation. Innovation could be directed towards developing more effective and less invasive diagnostic tools, and fostering breakthroughs in biologics and gene therapy with the potential to revolutionize treatment paradigms. Furthermore, fostering collaborations between academic institutions and biotech companies can spur research and expedite translation from bench to bedside. The nature of the market is dynamic, driven by constant advancements in technology and shifts in patient and healthcare provider preferences, necessitating agility and foresight in strategy formulation. Companies should thus focus on adaptive business models, ensuring flexibility and responsiveness to emerging trends and consumer needs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Prostate Health Market

The Prostate Health Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising aging population and increasing prevalence rate of benign prostatic hyperplasia and prostate cancer
  • Growing government's initiatives for advancement in technology in diagnosis
  • Innovation in hormone therapy drugs and developments genomics and proteomics
• Market Restraints
  • Side-effects associated with BPH medications
• Market Opportunities
  • Increasing researches leading to development of new drugs like Rucaparib and Olaparib
  • Development of novel modality of therapy for prostate cancer
• Market Challenges
  • Low awareness regarding prostate health

Porter's Five Forces: A Strategic Tool for Navigating the Prostate Health Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Prostate Health Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Prostate Health Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Prostate Health Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Prostate Health Market

A detailed market share analysis in the Prostate Health Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Prostate Health Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Prostate Health Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Prostate Health Market

A strategic analysis of the Prostate Health Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Prostate Health Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc., GlaxoSmithKline PLC, Ipsen Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Ltd..

Market Segmentation & Coverage

This research report categorizes the Prostate Health Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Benign Prostatic Hyperplasia, Prostate Cancer, and Prostatitis.
• Based on Therapy Type, market is studied across AR-Directed Therapies, Cytotoxic Agents, Hormone ADT, and Poly (ADP-Ribose) Polymerase (PARP) Inhibitors.
• Based on Drug Treatment Type, market is studied across 5-Alpha Reductase Inhibitors and Alpha Blockers. The 5-Alpha Reductase Inhibitors is further studied across Dutasteride and Finasteride. The Alpha Blockers is further studied across Alfuzosin, Doxazosin, Silodosin, and Tamsulosin.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising aging population and increasing prevalence rate of benign prostatic hyperplasia and prostate cancer
    • 5.1.1.2. Growing government's initiatives for advancement in technology in diagnosis
    • 5.1.1.3. Innovation in hormone therapy drugs and developments genomics and proteomics
  • 5.1.2. Restraints
    • 5.1.2.1. Side-effects associated with BPH medications
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing researches leading to development of new drugs like Rucaparib and Olaparib
    • 5.1.3.2. Development of novel modality of therapy for prostate cancer
  • 5.1.4. Challenges
    • 5.1.4.1. Low awareness regarding prostate health
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Prostate Health Market, by Disease Type

• 6.1. Introduction
• 6.2. Benign Prostatic Hyperplasia
• 6.3. Prostate Cancer
• 6.4. Prostatitis

7. Prostate Health Market, by Therapy Type

• 7.1. Introduction
• 7.2. AR-Directed Therapies
• 7.3. Cytotoxic Agents
• 7.4. Hormone ADT
• 7.5. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors

8. Prostate Health Market, by Drug Treatment Type

• 8.1. Introduction
• 8.2. 5-Alpha Reductase Inhibitors
  • 8.2.1. Dutasteride
  • 8.2.2. Finasteride
• 8.3. Alpha Blockers
  • 8.3.1. Alfuzosin
  • 8.3.2. Doxazosin
  • 8.3.3. Silodosin
  • 8.3.4. Tamsulosin

9. Americas Prostate Health Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Prostate Health Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Prostate Health Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Astellas Pharma Inc.
• 2. AstraZeneca PLC
• 3. Bayer AG
• 4. Bristol-Myers Squibb Company
• 5. Elekta AB
• 6. Eli Lilly and Company
• 7. F. Hoffmann-La Roche AG
• 8. Ferring Pharmaceuticals Inc.
• 9. GlaxoSmithKline PLC
• 10. Ipsen Limited
• 11. Merck & Co., Inc.
• 12. Novartis AG
• 13. Pfizer Inc.
• 14. Sanofi S.A.
• 15. Takeda Pharmaceutical Company Ltd.